- Home
- BRKR vs RGEN Comparison
BRKR vs RGEN Comparison
Compare BRKR & RGEN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- BRKR
- RGEN
- Stock Information
- Founded
- BRKR 1991
- RGEN 1981
- Country
- BRKR United States
- RGEN United States
- Employees
- BRKR N/A
- RGEN N/A
- Industry
- BRKR Biotechnology: Laboratory Analytical Instruments
- RGEN Medical/Dental Instruments
- Sector
- BRKR Industrials
- RGEN Health Care
- Exchange
- BRKR Nasdaq
- RGEN Nasdaq
- Market Cap
- BRKR 9.2B
- RGEN 7.6B
- IPO Year
- BRKR 2000
- RGEN N/A
- Fundamental
- Price
- BRKR $61.26
- RGEN $156.55
- Analyst Decision
- BRKR Buy
- RGEN Buy
- Analyst Count
- BRKR 13
- RGEN 12
- Target Price
- BRKR $75.67
- RGEN $187.44
- AVG Volume (30 Days)
- BRKR 1.4M
- RGEN 470.1K
- Earning Date
- BRKR 02-11-2025
- RGEN 02-19-2025
- Dividend Yield
- BRKR 0.33%
- RGEN N/A
- EPS Growth
- BRKR N/A
- RGEN N/A
- EPS
- BRKR 2.06
- RGEN N/A
- Revenue
- BRKR $3,241,300,000.00
- RGEN $633,513,000.00
- Revenue This Year
- BRKR $15.23
- RGEN $2.28
- Revenue Next Year
- BRKR $7.52
- RGEN $9.88
- P/E Ratio
- BRKR $30.54
- RGEN N/A
- Revenue Growth
- BRKR 15.00
- RGEN N/A
- 52 Week Low
- BRKR $48.07
- RGEN $113.50
- 52 Week High
- BRKR $94.86
- RGEN $211.13
- Technical
- Relative Strength Index (RSI)
- BRKR 58.41
- RGEN 60.07
- Support Level
- BRKR $58.78
- RGEN $149.15
- Resistance Level
- BRKR $64.64
- RGEN $160.64
- Average True Range (ATR)
- BRKR 1.98
- RGEN 5.96
- MACD
- BRKR 0.39
- RGEN 0.91
- Stochastic Oscillator
- BRKR 59.23
- RGEN 79.57
About BRKR Bruker Corporation
Bruker Corp manufactures scientific instruments and diagnostic tests for customers in the life sciences, pharmaceutical, and biotechnology industries. It operates in four operating segments: Bruker Scientific Instruments (BSI) BioSpin, BSI CALID, BSI Nano, and Bruker Energy and Supercon Technologies (BEST). The company generates maximum revenue from the BSI CALID segment. Geographically, it derives the maximum of its revenue from Asia Pacific.
About RGEN Repligen Corporation
Repligen, headquartered in Waltham, Massachusetts, is a global life sciences company that develops and sells bioprocessing equipment and supplies used in the manufacturing of biologic drugs, including monoclonal antibodies, recombinant proteins, vaccines, and cell and gene therapies. Its customers include biopharmaceutical companies, contract development and manufacturing organizations, or CDMOs, and other life science companies. It sells four main product categories: filtration (including fluid management) is the largest category and was 54% of 2023 revenue, while chromatography, proteins, and process analytics were 20%, 16%, and 9%, respectively. Customers in North America, Europe, and Asia Pacific contributed 44%, 37%, and 19% of revenue, respectively.